 Context Therapeutics NASDAQ:CNTX Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, to manufacture Contexts clinical development candidate CTIM-76. CTIM-76 is a Claudin 6 CLDN6 x CD3 T-cell engaging bispecific antibody targeting CLDN6 positive tumors, the company noted in a statement. 